Regulatory Approvals to Flourish the Global Migraine Drugs Market Growth

The global migraine drugs market is projected to grow at a CAGR of over 9% during the forecast period. The global migraine drugs industry has several players operating in the market and providing products for the treatment of migraine globally. Some of the prominent players operating in the global migraine drugs market are Allergan Plc, Amgen Inc., Novartis International AG, Eli Lilly & Co., GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co. Inc. Pfizer Inc., and Teva Pharmaceuticals Inc. among others. These players are significantly contributing to the global migraine drugs market and have a major share during the forecast period. 

Browse the full report description Global Migraine Drugs Market Size, Share & Trends Analysis Report by Treatment Type (Acute Migraine Treatment and Preventive Migraine Treatment), and by Route of Administration (Oral, Injectable, and Others), Forecast 2019-2025 at https://www.omrglobal.com/industry-reports/migraine-drugs-market

Some of the strategies that are majorly being adopted by these players include new products offering, expansion, partnership & collaboration, and mergers & acquisitions among others. For instance, Allergan's Ubrogepant and Eli Lilly's Lasmiditan are the migraine drugs based on the advanced mechanism of action. 

In February 2020, Biohaven Pharmaceutical Holding Co. Ltd.’s oral pill known as Nurtec ODT, chemically known as rimegepant was approved by the US FDA. This drug is consumed for dismissing the pain after the onset of migraine headaches. The dug falls under CGRP and directly competes with the first approved Allergan Plc’s Ubrelvy.

In December 2019, the migraine drug Ubrogepant (Ubrelvy) manufactured by Allergen Plc has been approved by the US FDA. Ubrogepant is the CGRP drug in tablet form which is meant to be taken immediately after the onset of migraines by adults. 

In September 2018, Ajovy, a migraine drug manufactured by Teva Pharmaceutical Industries Ltd. received US regulatory approval. Ajovy is an injectable drug that is to be taken in a few months for relieving migraines in adults.

In May 2018, Aimovig, the drug manufactured by Amgen Inc. received the US FDA approval. The drug is given monthly by self-injection and charges up to $575 monthly in the US. The company manufactured Aimovig in partnership with Novartis International AG, a Swiss multinational pharmaceutical company.

Current Market Trends Covered in the Global Migraine Drug Market Report:

• Increased healthcare spending and improving healthcare infrastructure is influencing the global migraine drugs industry growth during the forecast period.
• Shifting consumer preferences towards the use of injections for a quicker relief is expected to provide ample growth opportunities for market growth.
• The injection segment will account for significant growth in the market.
• The novel drug innovations, various regulatory approvals, and geographical expansions will be the key strategy of the players.
• North America region is expected to hold a prominent share in the migraine drugs market.

Global Migraine Drugs Market – Segmentation

By Type

• Acute Migraine Treatment
• Preventive Migraine Treatment

By Route of Administration

• Oral
• Injectable
• Others (Spray)

Global Migraine Drugs Market – Segmentation by Region 

North America           

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific    

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa 
• Latin America 

To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/migraine-drugs-market